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Abstract
Background: Whether metformin precipitates lactic acidosis in patients with chronic kidney disease (CKD) remains
under debate. We examined whether metformin use was associated with an increased risk of acute kidney injury
(AKI) as a proxy for lactic acidosis and whether survival among those with AKI varied by metformin exposure.
Methods: All individuals with type 2 diabetes and available prescribing data between 2004 and 2013 in Tayside,
Scotland were included. The electronic health record for diabetes which includes issued prescriptions was linked to
laboratory biochemistry, hospital admission, death register and Scottish Renal Registry data. AKI events were defined
using the Kidney Disease Improving Global Outcomes criteria with a rise in serum creatinine of at least 26.5 μmol/l or
a rise of greater than 150% from baseline for all hospital admissions. Cox Regression Analyses were used to examine
whether person-time periods in which current metformin exposure occurred were associated with an increased rate of
first AKI compared to unexposed periods. Cox regression was also used to compare 28 day survival rates following first
AKI events in those exposed to metformin versus those not exposed.
Results: Twenty-five thousand one-hundred fourty-eight patients were included with a total person-time of
126,904 person years. 4944 (19.7%) people had at least one episode of AKI during the study period. There
were 32.4 cases of first AKI/1000pyrs in current metformin exposed person-time periods compared to 44.9
cases/1000pyrs in unexposed periods. After adjustment for age, sex, diabetes duration, calendar time, number
of diabetes drugs and baseline renal function, current metformin use was not associated with AKI incidence,
HR 0.94 (95% CI 0.87, 1.02, p = 0.15). Among those with incident AKI, being on metformin at admission was
associated with a higher rate of survival at 28 days (HR 0.81, 95% CI 0.69, 0.94, p = 0.006) even after
adjustment for age, sex, pre-admission eGFR, HbA1c and diabetes duration.
Conclusions: Contrary to common perceptions, we found no evidence that metformin increases incidence of
AKI and was associated with higher 28 day survival following incident AKI.
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Background
Metformin is a biguanide which has been used as first
line therapy for the treatment of type 2 diabetes in
the United Kingdom since the 1960s. In addition to
its effectiveness as a treatment for type 2 diabetes,
there is increasing evidence of its beneficial cardiovas-
cular effects [1–6]. There is, however, considerable
debate regarding its use in patients with chronic
kidney disease (CKD), defined as an estimated Glom-
erular Filtration Rate (eGFR) of less than 60 ml/min/
1.732. Guidelines pertaining to metformin prescribing
and renal impairment vary. The United States Food
and Drug Administration (FDA) previously stated that
metformin was contraindicated in males with a serum
creatinine above 132.6 μmol/l and females above
123.8 μmol/l or abnormal creatinine clearance [7].
However, following a recent review of the literature,
these recommendations were revised to indicate that
metformin can now be used safely in patients with
mild renal impairment (eGFR 45- 60 ml/min/1.732)
and in some with moderate renal impairment (eGFR
<45 ml/min/1.732) [8]. The National Institute for
Health and Care Excellence (NICE) in the UK allows
prescribing of metformin in patients with an eGFR of
less than 60 ml/min/1.732 but recommends that the
dose is reduced in patients with an eGFR of less than
45 ml/min/1.732 (or serum creatinine of greater than
132.6 μmol/l) and metformin discontinued if eGFR is
less than 30 or serum creatinine greater than
150.3 μmol/l [9]. Current contraindications therefore
exclude its use in a large proportion of patients with
CKD [10]. Following the FDA’s announcement, the
European Medicines Agency (EMA) have also now
announced that metformin-containing medicines can
be used in patients with moderately reduced renal
function (eGFR 30 to 59 ml/min/1.732) [11].
The advent of a universally agreed serum creatinine
based definition for AKI allows identification of even
mild (Stage 1) AKI without relying on hospital coding
systems [12] allowing assessment of renal safety in
patients with CKD.
The present study therefore aimed to examine whether
current metformin use was associated with an increased
rate of AKI as a proxy for lactic acidosis compared to
non-use and to establish whether metformin exposure
affected survival in patients with AKI.
Methods
Study population
All adults over 18 between the 1st of January 2004 and
31st of December 2013 with type 2 diabetes and avai-
lable prescribing data who were resident or died in the
NHS Tayside region, Scotland formed the study cohort.
Ethical statement
Anonymised record linkage was conducted according to
Health Informatics Centre (HIC), University of Dundee
[13] Standard Operating Procedure (SOP). The Tayside
Research Ethics Committee does not require submission
of individual studies that follow this SOP which is
Caldicott Guardian approved.
Data sources
Data were linked using HIC [13], University of Dundee.
HIC enables anonymised health record linkage from the
population of Tayside (400000), Scotland, using a unique
identifying Community Health Index (CHI) number. Data
were linked between the following datasets: Scottish
Morbidity Record of hospital admissions (SMR01); labora-
tory results, medicines dispensed by community pharma-
cies, the Scottish Care Initiative-Diabetes Collaboration
(SCI-DC) and the Scottish Renal Registry (SRR). SMR01
provides information on age, sex, postcode and admission
and discharge dates. Creatinine measurements were
obtained from the laboratory system. SCI-DC provided
information on diabetes type and date of diagnosis. The
number of dispensed prescriptions over the previous year
prior to admission from community pharmacies, and
exposure to medications that predispose to renal impair-
ment (non-steroidal anti-inflammatory drugs (NSAIDs),
Cox-2 inhibitors, ACE-inhibitors and Angiotensin-II
receptor antagonists), were ascertained from dispensed
prescribing data. This dataset comprises of all community
dispensed prescribing from community pharmacies in
the Tayside region of Scotland. Patients receiving
chronic dialysis or post renal transplant were iden-
tified using the SRR.
Outcomes
All hospital admissions during follow up were evaluated
for the difference between the peak in-hospital and pre-
admission serum creatinine. AKI severity was defined
using the Kidney Disease Improving Global Outcomes
(KDIGO) creatinine based criteria. AKI was defined as
the rise in serum creatinine of at least 26.5 μmol/l or a
serum creatinine of greater than 150% of baseline serum
creatinine during admission [12]. Baseline creatinine was
defined as the median of all creatinine measurements
between 28 and 56 days prior to hospitalisation. Cases
were excluded if a baseline creatinine was not measured.
Estimated GFR was calculated using the Modification of
Diet in Renal Disease (MDRD) 4 formula [14]. The pri-
mary outcome for the survival analysis was all-cause
mortality within 28 days from the day of admission.
Statistical methods
All type 2 diabetes patients who were at least 18 years old
at diagnosis and were observable for drug prescriptions at
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some point during the study period were included. A
patient was considered observable if they had records of
drug prescriptions, with gaps of up to 180 days between
prescriptions allowed. Their entry date was calculated as
the latest of their date of diagnosis of diabetes, study entry
date (1/1/2004), and their drug observability (between
study start date and study end date (31/12/2013)). Follow-
up was censored at the earliest of death, study end date,
unobservability, or AKI event. The data was then split lon-
gitudinally into 28 day time slices, meaning each 28 days a
patient contributed to the study results in one row in our
data set. This allowed us to use time-updated covariates
(eGFR, number of diabetes drugs being taken, diabetes
duration, calendar time, ever/never metformin use, and
HbA1c). If more than one measurement (such as eGFR or
HbA1c) fell into the same time slice, the median was taken.
Patients who contributed less than 28 days of follow-up
were excluded. All observability stretches were extended
by 90 days as drug observability ceases during hospita-
lisation. Drugs were identified by their Anatomical Thera-
peutic Chemical (ATC) codes, and drug unobservability
meant a patient had not had a prescription of any drug
for more than 180 days.
Baseline characteristics (ie those identified closest to
study entry date) were displayed as mean and standard de-
viation (SD) or median and interquartile range (IQR) for
continuous variables depending on distribution. Catego-
rical variables were displayed as number and percentage.
Survival analysis
Cox regression analyses, comparing AKI rates in person-
time periods on metformin with AKI rates in person time
periods not on metformin, were used to calculate hazard
ratios (HR) and 95% confidence intervals adjusted for con-
founders. Confounders were selected based on literature,
guidelines and clinical expertise and were age, sex, dia-
betes duration, baseline renal function, calendar time and
number of diabetes drug classes [12, 15]. All analyses were
carried out in R. Sensitivity analysis was performed using
“ever” versus “never” exposure in place of current
exposure where “ever” was defined as at least one pre-
scription for metformin during the study period.
Results
Between 1st of January 2004 and 31st of December
2013, there were 25,148 patients with Type 2 diabetes in
the Tayside region of Scotland forming the study cohort.
14,622 of these patients were treated with metformin at
some point during the study period and 10,526 patients
were never on metformin during the study period. Total
person-time was 126,904 person years (pyrs) of which
60,738 pyrs were exposed to metformin. Median
duration of follow-up was 8.1 years IQR (5.2-10.0).
Demographic characteristics of the study population
at the study midpoint (1st July 2008) are described in
Table 1. The analysis conducted here is a time up-
dated analysis of rates in person-time periods (rather
than persons) associated with metformin exposure
compared to person-time periods without exposure
therefore we show the characteristics of person-time
periods associated with current metformin exposure
compared to person-time periods without current
exposure in Table 2. Metformin exposure periods oc-
curred at younger ages, higher HbA1c, longer duration
of diabetes and were associated with higher eGFR,
p < 0.0002.
During follow-up, 4944 people had at least one
episode of AKI during the study period. Of these AKI
events, 4352 were Stage 1, 140 Stage 2 and 452 Stage 3
AKI events. Only person-time periods to the first event
were included in analyses. The characteristics at entry
into the study of those persons who had an event at any
time during follow up versus those who did not are
shown in Table 3. Patients who had any AKI event had
lower eGFR at entry to the study than those who never
developed an event (median 58 ml/min/1.732 IQR 46-70
vs 73 ml/min/1.732 IQR 61-88). AKI was strongly
associated with pre-admission eGFR (Table 4).
Overall incidence of AKI was 39.0 cases/1000 pyrs.
There were 32.4 cases of AKI/1000pyrs in person-time
periods with current metformin use compared to 44.9
Table 1 Demographic characteristics of cohort at study
midpoint 1st July 2008, n = 12,373
Age in yearsa 68.2 (59.2-75.9)
Sex (M) (%) 6636 (54)
Metformin Use (%) 5975 (48)
Diabetes Duration in yearsa 5.48 (2.50-9.91)
Number of diabetes drug classes prescribed (%)
0 4187 (33.8)
1 4517 (36.5)
2 2943 (23.8)
3 671 (5.4)
4 53 (0.4)
5 2 (0.02)
eGFR category (%)
>60 8926 (72.1)
30-59 2574 (20.8)
<29 ml/min/1.732 180 (1.5)
Missing 693 (5.6)
HbA1c % 7.0 (6.3 – 7.9)
(mmol/mol) 53 (45- 63)
ACE inhibitor or ARB Use (%) 5074 (41%)
NSAID or Cox-2 inhibitor use (%) 1160 (9.4%)
aMedian & IQR
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cases/1000pyrs during person-time periods in which
metformin was not being used. Severity of diabetes was
adjusted for by adjusting for diabetes duration and num-
ber of diabetes medicines. Current metformin use was as-
sociated with a lower AKI rate, HR 0.76 (95% CI 0.70,
0.82, p < 0.0001) after adjustment for sex, current age,
current diabetes duration, and current number of diabetes
drugs. When further adjusted for baseline renal function,
current metformin use was no longer associated with any
difference in AKI rate, HR 0.94 (95% CI 0.87, 1.02,
p = 0.15). After including current or “ever” metformin
use, person-time periods with current or “ever” exposure
to metformin were associated with higher rates of AKI
than person-time periods with no current or prior expos-
ure; HR 1.13 (95%CI 1.05, 1.22, p = 0.001).
At study midpoint only 1.5% of people with an eGFR
<30 were taking metformin compared to 72% of people
with an eGFR >60. Clearly since current eGFR is a
strong correlate of metformin exposure and predicts
future AKI events, disentangling drug effects from
allocation effects is difficult and negative confounding
by allocation could explain the hazards ratio (HR) ob-
served. In addition to adjusting for baseline eGFR in the
Cox regression, we also examined whether, among strata
of person-time periods defined by baseline eGFR,
whether there was any evidence of an effect of metfor-
min. We found no evidence of increased rates of AKI-
even where baseline eGFR was <30, the rates of events
in person-time periods exposed to metformin were not
greater than those unexposed to metformin (Table 5).
Furthermore we conducted a sensitivity analysis where
we adjusted for lagged eGFR – i.e. for each time periods
we included a time updated covariate which was eGFR
6 months prior to that time period as distinct from the
baseline eGFR as that may have long preceded that
person-time period. This analysis allows for a fuller
adjustment of the effect of prevailing eGFR on the prob-
ability of metformin exposure. In this analysis the HR
for current metformin exposure was 0.85 (95%CI 0.78,
0.92), p < 0.0001.
Note that since it could be argued that the probability
of subsequent exposure to metformin (either for the first
time or repeat prescription) may be altered when an
AKI event has occurred, person- time was right cen-
sored at the first AKI event for this part of the analyses.
Survival
Table 6 show the characteristics of those AKI events
where there was current metformin exposure compared
to events not associated with current exposure. Of pa-
tients with AKI, 844 died within 28 days of admission.
Death rate was 23.5 (per 1000 pyears of follow-up): 7.9
in patients on metformin vs 15.6 in patients not on met-
formin per 1000 pyears. Conditional on the AKI event
occurring, metformin use at admission was associated
with a lower risk of death at 28 days (HR 0.81, 95% CI
0.69, 0.94, p = 0.006) even after adjustment for age, sex,
pre-admission eGFR, HbA1c and diabetes duration.
Following further adjustment for use of ACE inhibitor
or ARB, use of NSAIDs or Cox-2 inhibitors and number
of prescribed medicines as a proxy for co-morbidity, this
effect persists (HR 0.82, 95% CI 0.70, 0.95, p = 0.01).
When examining longer term mortality to the end of
2013 in those who had experienced an AKI event, risk of
death subsequent to an AKI event not on metformin
was higher HR 1.32 (95%CI 1.23, 1.43, p < 0.0001) than
Table 2 Summary patient characteristics by metformin
exposure status
Metformin exposed
periods
Metformin unexposed
periods
(60,738.1 years) (66,165.9 years)
Age (Years) a 65.7 (57.3 - 73.5) 70.2 (61.1 – 78.1)
HbA1c % 7.3 (6.7- 8.3) 6.7 (6.2- 7.6)
(mmol/mol) a 56 (50 – 67) 50 (44 - 60)
Diabetes Duration
(years) a
6.9 (3.7 – 11.2) 4.3 (1.8 – 8.9)
eGFR category (%)
>60 44,830.6 (73.8) 39,332.4 (59.4)
30-60 12,575.1 (20.7) 18,775.3 (28.3)
<30 ml/min/1.732 236.8 (0.4) 1592.7 (2.4)
ACE/ARB use (%) 25,572.6 (42) 21,827.7 (33)
NSAID use (%) 5967.4 (10) 6140.8 (9)
aMedian & IQR
Table 3 Characteristics of patients developing/ not developing
AKI at entry into study
AKI event during
follow-up
No AKI event during
follow-up
(n = 4944) (n = 20,204)
Age (Years) a 71.7 (64.7 – 78.3) 63.4 (54.2 – 72.1)
Male Sex (%) 2694 (54.5) 11,031 (54.6)
HbA1c % 7.2 (6.4- 8.3) 7.0 (7.4- 8.4)
(mmol/mol) a 55 (46 – 67) 53 (45 - 68)
Diabetes Duration (years) a 0 (0 – 3) 3.3 (0 – 9)
Number of diabetes drug classes (%)
0 2583 (52) 14,212 (70)
1 1617 (33) 4471 (22)
2 706 (14) 1438 (7)
3 27 (0.5) 76 (0.4)
4 1 6
5 0 1
ACE/ARB use (%) 1505 (30) 4667 (23)
NSAID use (%) 474 (10) 2079 (10)
aMedian & IQR
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risk of death with AKI treated with metformin HR 1.15
(95%CI 1.06, 1.25, p = 0.002) after adjustment for age,
sex, baseline renal function, HbA1c and diabetes
duration.
Discussion
In this large cohort of over 25,000 patients with Type 2
diabetes, we found no evidence of any adverse effect of
current metformin use on AKI incidence or on survival
following AKI across different eGFR strata. We have
shown risk of AKI does not differ during person-time
periods where there was no current metformin exposure
compared to those in which there was current met-
formin exposure.
Strengths of our study include the large cohort size with
high metformin use. We identified our cohort using the
SCI-Diabetes system. This system is used to record all dia-
betes clinical care in Scotland thereby capturing 99% of
patients with diabetes [16]. Furthermore, prescribing data
was obtained from pharmacy dispensed prescriptions
(covering all pharmacies in the Tayside region) rather than
prescriptions alone increasing reliability that the medi-
cines are actually being taken. AKI was defined using the
KDIGO creatinine based criteria from laboratory data that
are only available at regional level [12].
Observational pharmaco-epidemiology studies have to
contend with various potential biases or confounders.
The most difficult bias for this study is negative
confounding by allocation wherein those with a lower
eGFR are more likely to develop AKI but less likely to
be exposed to metformin. We attempted to address this
by adjustment for eGFR in a number of ways and by
conducting analyses by different strata of eGFR. None of
the analyses showed any suggestion of an adverse effect.
Since there are unlikely to be randomised trials of
allocating metformin to those with low eGFR to assess
safety, this observational study provides useful reassur-
ance that we cannot see any adverse safety signals in the
data that would warrant a change to the current
guidelines. If anything the data suggest that the current
guidelines may be too stringent and could be relaxed
further. We used multivariable analysis to adjust for im-
portant clinical confounders in view of the difference be-
tween the metformin users and the non-metformin
users. Furthermore, our data may not be applicable to
other populations as the Tayside region of Scotland lacks
ethnic diversity and is predominantly of European ances-
try. In addition, we were unable to use direct data on
co-morbidity due to problems of under reporting [17].
We therefore used number of prescribed medications
prior to admission which has been shown to correlate
well with co-morbidity [18]. A further limitation of our
Table 4 Distribution of AKI incidence by baseline eGFR and AKI stage
eGFR (ml/min/1.732)
AKI Stage <30 30-60 >60
n Person time
(years)
Incidence rate
(per 1000 person-years)
n Person time
(years)
Incidence rate
(per 1000 person-years)
n Person time
(years)
Incidence rate
(per 1000 person-years)
1 439 1829 240 2187 31,350 70 1717 84,163 20
2 16 1829 8.7 43 31,350 1.3 81 84,163 1.0
3 167 1829 91 142 31,350 4.5 129 84,163 1.5
Table 5 Hazard ratios (95% CI) for AKI associated with
metformin exposure compared to non-exposure by baseline
eGFR
eGFR (ml/min/1.732) <30 30-60 >60
Number of events 88 733 681
HR (95% CI) 0.45 (0.10,1.91) 0.80 (0.66,1.0) 0.76 (0.62,0.95)
p 0.28 0.05 0.01
Table 6 Characteristics of patients who developed AKI during
follow-up (n = 4944)
Metformin exposed
AKI event
AKI event without concurrent
metformin exposure
(n = 1972) (n = 2972)
Age (Years) a 73.6 (65.7 – 79.4) 77.6 (70.4-83.7)
Male Sex (%) 1161 (58.9) 1533 (51.6)
HbA1c % 7.2 (6.5- 8.3) 6.8 (6.2- 7.9)
(mmol/mol) a 55 (48- 67) 51 (44- 63)
Diabetes Duration
(years) a
9.15 (5.11- 13.85) 7.50 (3.30-13.76)
Number of diabetes drug classes (%)
0 13 (0.7) 1745 (58.7)
1 830 (42.1) 1049 (35.3)
2 897 (45.5) 162 (5.5)
3 212 (10.8) 16 (0.5)
4 19 (1.0) 0 (0.0)
5 1 (0.1) 0 (0.0)
CKD category (%)
>60 941 (47.7) 986 (33.2)
30-59 896 (45.4) 1476 (49.37)
<29 ml/min/1.732 130 (6.6) 492 (16.6)
aMedian & IQR
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study was that we were unable to account for over the
counter NSAID use in our population.
Reported incidence rates of metformin associated
lactic acidosis are in fact very low further supporting
its more widespread use. A Cochrane review showed
no cases of fatal or non-fatal lactic acidosis in 70, 490
patient- years of metformin use [19]. Incidence rates
of MALA were 3.3 per 100,000 person-years in a
nested case control analysis of 50,048 patients from
the United Kingdom General Practice Research Data-
base compared with 4.8 per 100,000 person-years
among sulphonylurea users [20]. Several studies have
shown use of metformin in patients with renal
impairment thereby suggesting non-adherence to
guidelines [21–25]. In a subgroup analysis of 6960 pa-
tients with eGFR 45-60 ml/min/1.732 from a Swedish
cohort of 51, 675 patients, there was a significantly
lower risk of acidosis/ serious infection in patients on
metformin and a slightly higher but insignificant risk
in the subgroup of 2044 patients with eGFR of 30-
45 ml/min/1.732 [2]. A systematic review examining
patients with CKD demonstrated the safety of metfor-
min in patients with stable CKD (eGFR >30 ml/min/
1.732) including 150,000 patients. This concluded that
rates of lactic acidosis were low and similar to that of
sulphonylureas [26]. A more recent systematic review
showed similar results suggesting that risk of lactic
acidosis is low and indistinguishable from background
risks and that available evidence supported expansion
of metformin in patients with CKD with appropriate
dose reduction and follow-up [27].
Despite almost 60 years of metformin use, there is
a lack of pharmacokinetic studies of metformin in
patients with CKD. Metformin inhibits the mitochon-
drial respiratory chain. This impairs energy metabol-
ism aerobically leading to increased anaerobic
metabolism thereby generating lactate [28]. Metformin
is eliminated unchanged by the kidney therefore it
can accumulate in patients with renal impairment in-
creasing the risk of lactic acidosis. In a small study of
15 patients administered 850 mg of metformin, mild
CKD (creatinine clearance, 60-90 mL/min) was associ-
ated with 23% to 33% reductions in medication clear-
ance and moderate CKD(30-60 mL/min) with 74% to
78% reductions [29]. Whilst safety of metformin has
been shown in patients with mild renal impairment,
dose reduction is advisable. Further pharmacokinetic
studies are required to establish safe dosing in
patients with moderate to severe renal impairment.
It has previously been shown in animal models that
metformin exerts a nephrotoxic effect [30]. However,
there is a lack of data in humans to support this. A
recent retrospective cross sectional study showed that in
a small number of patients, with previously normal renal
function, admitted with AKI, metformin use was associ-
ated with both lactic acidosis and worsening AKI in a
dose related manner. They did not, however, demon-
strate a difference in survival or need for RRT [31].
There is increasing evidence that AKI is associated
with increased mortality even with stage 1 [32–34] AKI.
Our data found that survival rates were higher in pa-
tients with AKI previously treated with metformin com-
pared to patients with AKI not previously on metformin.
This is in line with several previous observational studies
in which lower event rates in those exposed to metfor-
min persists even in subgroups with impaired renal
function [2, 4]. A Swedish study of 51,675 people with
Type 2 diabetes found that those treated with metformin
monotherapy had a lower risk of fatal or non-fatal car-
diovascular disease events and all-cause mortality [2]. In
a multicentre cohort of 19,691 diabetic patients with
atherothrombosis, mortality rates were lower in patients
treated with metformin compared to those not on
metformin. This association persisted in a subgroup of
patients with CKD (eGFR 30-60 ml/min/1.732) [4]. A re-
cent review of metformin use in patients with kidney
disease recommended that metformin could be used in
patients with an eGFR of 30-60 ml/min/1.732 with dose
reduction [27]. Following this review the FDA have re-
vised their recommendation stating that it can be used
in mild renal impairment and in some with moderate
renal impairment [8]. It is difficult to ascertain whether
the survival benefit we have shown is due to selection
bias in that patients who receive metformin may be a
different cohort in that they are fitter. However, we have
shown that in our data patients on metformin actually
had a longer duration of diabetes and higher HbA1c
levels suggesting that the survival benefit may be due to
the known beneficial effects of metformin on vascular
endothelium rather than selection bias.
Whilst renal safety of metformin is important in its
own right, we were also motivated to analyse AKI rates
as a proxy for lactic acidosis. It is difficult to ascertain
the true incidence of Metformin associated lactic aci-
dosis (MALA). Observational studies may either over or
underestimate incidence of MALA [35–37]. Most cases
of MALA are multifactorial with other factors contribut-
ing to lactic acidosis such as sepsis, cardiac, respiratory
or hepatic failure. Studies can be subject to ascertain-
ment bias with fitter patients being selected for
treatment with metformin. In addition, patients on met-
formin are more likely to have lactate levels measured
leading to the potential for overestimation of MALA.
International Statistical Classification of Diseases and
Related Health Problems 10th Revision (ICD −10) cod-
ing in isolation cannot be used in observational studies
to establish cases of MALA due to a lack of specific code
for lactic acidosis and many studies have not included
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patients with CKD. It is therefore difficult to establish
the safety of metformin in patients with CKD. We there-
fore examined hospitalisations with AKI in patients
treated with metformin as clinically significant lactic
acidosis occurs in the presence of AKI. Whilst we can-
not draw conclusions regarding the rates of MALA in
patients with CKD, we have shown that metformin use
does not adversely affect mortality which is reassuring.
This is arguably more clinically significant than actual
rates of MALA.
Conclusion
Our large cohort of metformin users provides a reassu-
ring message of the safety of metformin in patients with
or without a background of CKD and supports the re-
cent revision of FDA and EMA guidance on metformin
prescribing in patients with renal impairment. We have
also demonstrated that metformin does not adversely
affect survival in patients with AKI.
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